Zydus Lifesciences shares leap 6% on buyback buzz; co publicizes $166 mn Assertio acquisition
Zydus Lifesciences shares climbed to an intraday excessive of Rs 993.80 on Thursday. The inventory is up about 8% over the previous month and 10% over the previous 12 months. Over the long term, Zydus Lifesciences has delivered a 93% return in three years and practically 61% over 5 years.
Zydus Lifesciences share buyback
In an trade submitting launched on Wednesday, Zydus Lifesciences introduced that its board of administrators will meet on Might 19 to contemplate and approve its outcomes for the January-March quarter of the monetary 12 months 2026. Together with the earnings, the board may also think about a proposal to purchase again totally paid-up fairness shares of the corporate, it additional mentioned.
This comes after Zydus Lifesciences’ Rs 600 crore share buyback at a worth of Rs 1,005 apiece through the tender route. The buyback worth implied a premium of practically 9% from the extent at which the inventory was buying and selling on the document date. Earlier than that, the corporate executed a Rs 750-crore share buyback in 2022.
Zydus Lifesciences publicizes acquisition of Assertio Holdings
Zydus Lifesciences on Wednesday introduced that it has entered into an settlement to accumulate US-based pharma firm Assertio Holdings for $166.40 million. Assertio is concentrated on speciality and oncology supportive-care therapies.
“Zydus Worldwide DMCC, a subsidiary of the corporate, has signed a definitive settlement, by means of its wholly owned acquisition subsidiary Zara Merger Sub Inc, with Assertio Holdings to accumulate all excellent shares of Assertio for $23.50 per share in money,” in keeping with the assertion.
Additionally learn: NLC India shares rally 18% to contemporary document excessive after This fall internet revenue skyrockets 189% YoYThis comes after The Financial Occasions reported that Zydus Lifesciences is near buying a US-based drugmaker. Sources within the funding banking circles advised ET that Zydus will get a lift for the reason that goal firm has its personal pipeline of biologic medication. For a number of months, Zydus Lifesciences has been taking a look at methods to develop its pipeline of revolutionary medication. It was additionally seen in discussions with Ardelyx a couple of months in the past, however the talks didn’t materialise. “Zydus has been in discussions with a minimum of three firms,” the supply talked about.
(Disclaimer: Suggestions, recommendations, views and opinions given by the specialists are their very own. These don’t signify the views of The Financial Occasions)
